2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Apoptosis
  3. Reactive Oxygen Species Apoptosis
  4. Bixin

Bixin, isolated from the seeds of Bixa orellana, is an orally active carotenoid. Bixin induces apoptosis in cancer cells. Bixin possessing anti-inflammatory, anti-tumor and anti-oxidant activities. Bixin treatment ameliorated cardiac dysfunction through inhibiting fibrosis, inflammation and reactive oxygen species (ROS) generation.

For research use only. We do not sell to patients.

Bixin Chemical Structure

Bixin Chemical Structure

CAS No. : 6983-79-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Bixin:

Bixin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Bixin

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bixin, isolated from the seeds of Bixa orellana, is an orally active carotenoid. Bixin induces apoptosis in cancer cells. Bixin possessing anti-inflammatory, anti-tumor and anti-oxidant activities. Bixin treatment ameliorated cardiac dysfunction through inhibiting fibrosis, inflammation and reactive oxygen species (ROS) generation[1][2].

IC50 & Target

ROS generation[1]
In Vitro

Bixin (20-80 μM, 24 h) improves Lipopolysaccharides (LPS) (HY-D1056)-induced fibrosis in H9C2 cells without cytotoxicity[1].
Bixin (20-80 μM, 24 h) reduces inflammation response via TLR4/NF-kB inactivation in H9C2 cells[1].
Bixin (20-80 μM, 24 h) down-regulates ROS production in LPS-induced H9C2 cells via activating Nrf2[1].
Bixin (0-500 μM, 48 h) has anti-proliferative activity on human lung cancer (A549), cervical cancer (HeLa), and breast cancer (MCF-7)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bixin Related Antibodies

Cell Viability Assay[1]

Cell Line: H9C2 (Human cardiac muscle cell)
Concentration: 2.5, 5, 10, 20, 80 μM
Incubation Time: 0-72 h
Result: Showed no significant cytotoxicity to cardiac muscle cells H9C2.

Western Blot Analysis[1]

Cell Line: H9C2 (Human cardiac muscle cell)
Concentration: 20, 40 , 80 μM
Incubation Time: 24 h
Result: Reduced LPS induction up-regulated fibrosis-related signals expression in a dose-dependent manner. Reduced nuclear factor of activated T cells isoforms c3 (NFATc3), GATA4 and A-type natriuretic peptides (ANP) protein expression levels. Reduced fTLR4, MyD88, p-IKKα, p-IκBα and p-NF-κB expression enhanced by LPS. Reduced fibrosis levels via collagen deposition down-regulation.

Cell Proliferation Assay[2]

Cell Line: A549, HeLa, and MCF-7
Concentration: 0-500 μM
Incubation Time: 48 h
Result: Shows profound results on three types of cells, especially HeLa and MCF-7, with the crude extract having greater activity than the isolate. IC50 of crude extract were 185.54, 17.90, and 2.06 μM, while IC50 of isolated were 259.38, 43.87, and 14.38 μM against A549, HeLa, and MCF-7 cells, respectively.

RT-PCR[1]

Cell Line: H9C2 (Human cardiac muscle cell)
Concentration: 20, 40 , 80 μM
Incubation Time: 24 h
Result: Reversed SOD1, Nrf2, HO-1, CAT and GCLM mRNA levels in H9C2 cells restrained due to LPS treatment in a dose-dependent manner.
In Vivo

Bixin (50-200 mg/kg; p.o.; once a day for 14 weeks) attenuates inflammatory response by reducing pro-inflammatory cytokines secretion via Toll-like receptor 4 (TLR4)/ NF-κB signaling pathway inactivation in mice induced by high fat diet[1].
Bixin (50-200 mg/kg; p.o.; once a day for 14 weeks) restrains systemic metabolism disorder in high fat diet-induced mice[1].
Bixin (200 mg/kg, p.o.; once a day for 14 weeks) ameliorates high fat diet-induced heart failure in mice[1].
Bixin (50-200 mg/kg; p.o.; once a day for 14 weeks) reduces reactive oxygen species (ROS) generation in high fat diet-induced mice due to Nrf2 activation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male, 6-8 weeks, C57BL/6 mice weighed 20-25 g [1]
Dosage: 200 mg/kg
Administration: Oral gavage (p.o.); once a day for 14 weeks
Result: Reduced mice heart size induced by high fat feeding from appearance, accompanied with decreased ratio of heart weight to body weight.
Reduced the diameter of myocytes.
Down-regulated fibrosis area in HFD-fed mice.
Reversed left ventricular systolic pressure (LVSP) stimulated by high fat diet.
Displayed suppressive role in controlling the percentage of ejection fraction (EF), fractional shortening (FS), and anterior wall thickness (AWT).
Animal Model: Male, 6-8 weeks, C57BL/6 mice weighed 20-25 g [1]
Dosage: 50, 100, 200 mg/kg
Administration: Oral gavage (p.o.); once a day for 14 weeks
Result: Suppressed the insulin resistance induced by high fat diet (HFD) in a dose-dependent manner.
Reduced body weight caused by high fat diet in a dose-dependent manner.
Showed inhibitory role in low density lipoprotein cholesterol (LDLC), triglyceride (TG) and cholesterol (TC) levels.
Increased high density lipoprotein cholesterol (HDLC) due to HFD in a dose-dependent manner.
Reduced serum endotoxin in dose-dependent manner.
Impeded pro-inflammatory such as cytokines serum IL-1b, TNF-a and IL-18 releasing.
Reduced TLR4 and MyD88 expression from protein levels.
Could reverse HFD-induced heart injury through reducing ROS generation dependent on Nrf2 activation
Clinical Trial
Molecular Weight

394.50

Formula

C25H30O4
CAS No.
Appearance

Solid

Color

Brown to reddish brown

SMILES

OC(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)\C=C\C(OC)=O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 7.14 mg/mL (18.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5349 mL 12.6743 mL 25.3485 mL
5 mM 0.5070 mL 2.5349 mL 5.0697 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 0.71 mg/mL (1.80 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 0.71 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 0.71 mg/mL (1.80 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 0.71 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.53%

SDS (393 KB)

COA (251 KB) HNMR (275 KB) RP-HPLC (211 KB) MS (81 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5349 mL 12.6743 mL 25.3485 mL 63.3714 mL
5 mM 0.5070 mL 2.5349 mL 5.0697 mL 12.6743 mL
10 mM 0.2535 mL 1.2674 mL 2.5349 mL 6.3371 mL
15 mM 0.1690 mL 0.8450 mL 1.6899 mL 4.2248 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bixin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bixin6983-79-5Reactive Oxygen SpeciesApoptosisanti-inflammatoryanti-tumoranti-oxidant activitiesBixa orellanacarotenoidcardiac dysfunctionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bixin
Cat. No.:
HY-N6884
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.